HUE028331T2 - N-11-csonkolt ß-amiloid elleni monoklonális ellenanyag, készítmény, eljárás és alkalmazás - Google Patents

N-11-csonkolt ß-amiloid elleni monoklonális ellenanyag, készítmény, eljárás és alkalmazás Download PDF

Info

Publication number
HUE028331T2
HUE028331T2 HUE03798156A HUE03798156A HUE028331T2 HU E028331 T2 HUE028331 T2 HU E028331T2 HU E03798156 A HUE03798156 A HU E03798156A HU E03798156 A HUE03798156 A HU E03798156A HU E028331 T2 HUE028331 T2 HU E028331T2
Authority
HU
Hungary
Prior art keywords
antibody
ser
human
leu
peptide
Prior art date
Application number
HUE03798156A
Other languages
English (en)
Inventor
Marc Hubert Mercken
Marc Maria Pierre Pelagie Vandermeeren
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HUE028331T2 publication Critical patent/HUE028331T2/hu

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (7)

  1. hidÎ-CSONKOO' ß-AMILÖÖ> ELLENI MÖN0KLCE4ÁLÍI ELLEN ANYAGI, KÉSEÍTMENY, ELJÁRÁS ÈS ALKALMAZÁS Szabadalmi 8gé»y|m»tí>k t, Mooekletiâlis: dlenaayag, amelÿ specitikussn Mispmn aa ABlLMtérje <3teH-nàl BACH-l-gyel fortém hasítása «tán kapott Aßll-x pepiidet egyéb Akfoiragpiensékre adott kermzírsatóo. aéïfâl, ahol a ímmokkieáMS ellenanyag specifikusán folisæen «à {EsàdsïeiàzjLÎ hasítási hely «IsS 5-7 batöáte amiaosavät, mm a Seq Mbfo,:l és Saq là. No.;2 szerinti szekvenciát, vagy az ß-sBekreta;;Π hasítási hs% első 5-? sgéréradátii mmaôsavâh mm a Seq M bio.:3 és Seq U Hfofo szedné szekvenciát. Ί M L Igénypetst saersaÁ mpaokíoösiis ellenanyag, azzal jelkstezw, hogy áz Api 1A pepiid emberi Api 1-40.
  2. 3. Ás L vagy 2. igénypont szerinti ellenanyag, amely kim«talítstő modo« címkézett. 4, A 3. igénypont szenmi ellenanyag, ahol a ksnutatható eímfce mdioaktív jelölés, enzi®}efolé§, laaakesssceas jelölés vagy ttuoreszeens jelölés,
  3. 5, Az Id/igëaypostok bâiftïdyike szerinti eUeaaayag»-aaa^ly .feordözétt immoinikáli.
  4. 6. As I -S. igétrypontok hàmfoiyike szerinti ellenanyag, assoiym à Belgiaa Coordinated Collections of Mfcrootganteaas-nál 2003. angosztus \9'φ&amp; rendié LMBP 5;#6CB ás LMBP 5897CB letéti szám«» letétbe helyeselt jMPRD/feAßl 3/1 ás MJPRDdxÄßil/2 htbndomaseitek Mpresszalsmk. %. A 20()2. augusztus IR-en a Belgian Coordinated Collections of Microorgamsms-ml rendre LMBP 5896CB és LMBP 5897CB: letéti számon létéibe helyezett I&amp;JFRD/feApil/l és JMPRD/hAßU/2 hilmdómasejtek
  5. 8, Isununvizsgáiati módszer mtniabsö AFMshárje Clitl Bőéi BACEd-gyel történt hasítása után kapott Aßii-x pepiM meghatárosására vagy kimutatására, amely eljárás magában foglalja a minta érintkezietését 1-3. Igénypontok bármelyike szerinti, AßlLx pepiid elleni ellenanyaggal és annak meghatározását, bogf képződött' e komplex az ellenanyag; és az Aßl l-x peptid közöm % B||áíás szövetmintában AFF-febérjs Olull-aéi BACiE-l-gyél tânèni háshásá «ián kapott Aßl l-x pepttl! jelenlétének kimutatására, amely eljárás- magában foglalja a kővetkezőket: alahy iésfoffoi származó szőveímlma. édntkeztetése képalkotó eljárásban hatásos mennyiségű, 3. vagy 4. igénypont szériöít, kitntdathfoban uiíttkézeít ellenanyaggal, ás «..címke kknutaiása, ezáltal a szőveímmtáfean az Api 1 -x pepiid jeksiétáuek mégáüapitása. 19. A % igénypontszerinti eljárás, ahol a tómwiaih»tó «iodes címkézett ellenanyagi« a 6. igénypont szénné, legalább egyik bsbridómare.·t espresszálja
  6. 11. BÍíms tesífoiyssdékOiiíííábsn APF-Míé# Gla'l 1-náJ BACE-l-gye! tósléni hasítása mán kapott Aß| 1-X pepiid jelenlétének kímaiatására, aœ# «yáras magában fdgiaí|a a követelőket: alanjr testiből .gteató i«stíöl>nddkfp5«ía: árimkeztetáss képalkotó eljárásban hatásos mentsyiségá*· 3. vagy 41 igénypom szerinti, kte^^ltósít.stofc^ett4ite»aaya^:al, és scímke kíístitaldsa. ezáltal a testKslyaPokmístában az Mbi-x peptid jólonláténektnegáíainiása. i%. A 11, igénypont szerinti etjárás, almi a Mmoíatbalóa« CiöAégetíi eilemmyágot a ?. igénypont szerinti legalább egy tk éibrklémasejl: exprexszália,
  7. 13, M Eb, ígésypoPtok básöí&amp;lyíke szeréi« «liena-iyag alkalmazása ß-anbioidbsi kapcsolatos betegség ín vkro diagnoszíszállsáza, 14; Diagnosztikai készítmény, aso# Wtátoaz 1-6. fénypontok bármelyike szcrM ellenanyagot és gyógjAszatilag el'fógadbató hordozót. iS, Ipipmhyjzsgslatra szolgáló készlet jhamiloiddai kapcsolatos betegség: diagrmsztizáiására, amely tanalmaz 2-S. igéoyponiöípbármslyike szénát! eSmaayagot és hordozol sz eilenääiysg szársíéra.
HUE03798156A 2002-09-27 2003-09-09 N-11-csonkolt ß-amiloid elleni monoklonális ellenanyag, készítmény, eljárás és alkalmazás HUE028331T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2002/011062 WO2004029629A1 (en) 2002-09-27 2002-09-27 N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses

Publications (1)

Publication Number Publication Date
HUE028331T2 true HUE028331T2 (hu) 2016-12-28

Family

ID=32039081

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE03798156A HUE028331T2 (hu) 2002-09-27 2003-09-09 N-11-csonkolt ß-amiloid elleni monoklonális ellenanyag, készítmény, eljárás és alkalmazás

Country Status (13)

Country Link
US (2) US9329189B2 (hu)
EP (1) EP1546734B1 (hu)
JP (3) JP2006513988A (hu)
CN (2) CN101367875B (hu)
AU (1) AU2003266378B2 (hu)
CA (1) CA2498058C (hu)
CY (1) CY1117387T1 (hu)
DK (1) DK1546734T3 (hu)
ES (1) ES2560853T3 (hu)
HU (1) HUE028331T2 (hu)
PT (1) PT1546734E (hu)
SI (1) SI1546734T1 (hu)
WO (2) WO2004029629A1 (hu)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
WO2004029629A1 (en) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EA200501524A1 (ru) * 2003-03-28 2006-06-30 Сентокор, Инк. Антитела против амилоида, композиции, способы и применения
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
WO2006039470A2 (en) * 2004-09-29 2006-04-13 Centocor, Inc. Anti- amyloid antibodies, compositions, methods and uses
ES2259270B1 (es) * 2005-03-09 2007-11-01 Consejo Superior De Investigaciones Cientificas Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal.
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
EP1959996A2 (en) * 2005-12-12 2008-08-27 AC Immune S.A. Monoclonal antibody
JP5103466B2 (ja) * 2006-03-30 2012-12-19 グラクソ グループ リミテッド アミロイド‐βペプチドに対する抗体
US20100028351A1 (en) * 2006-06-29 2010-02-04 Marc Mercken Anti-amyloid antibodies, compositions, methods and uses
EP2046833B9 (en) * 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
US8323654B2 (en) 2007-05-14 2012-12-04 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US7931899B2 (en) 2007-05-14 2011-04-26 Medtronic, Inc Humanized anti-amyloid beta antibodies
ES2529174T3 (es) * 2007-06-12 2015-02-17 Ac Immune S.A. Anticuerpos humanizados para amiloide beta
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
BRPI0818623A2 (pt) * 2007-10-05 2017-05-23 Ac Immune Sa composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal
AU2008311367B2 (en) * 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
US20100074901A1 (en) * 2007-10-15 2010-03-25 Marc Hubert Mercken Human anti-amyloid antibodies, compositions, methods and uses
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2586797A3 (en) * 2007-11-27 2013-07-24 Medtronic, Inc. Humanized anti-amyloid beta antibodies
CN101463085B (zh) * 2009-01-16 2011-09-14 清华大学 与A-beta寡聚体特异性结合的基因工程单克隆抗体
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2598882B1 (en) 2010-07-30 2017-07-26 AC Immune S.A. Safe and functional humanized antibodies for use in treating an amyloidosis
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
CA2828433C (en) * 2011-03-16 2020-08-04 Probiodrug Ag Diagnostic antibody assay
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
JP6499079B2 (ja) 2012-11-13 2019-04-10 バイオエヌテック アーゲーBioNTech AG クローディンを発現するガン疾患を処置するための剤
EP3594240B1 (en) 2013-05-20 2023-12-06 F. Hoffmann-La Roche AG Anti-transferrin receptor antibodies and methods of use
WO2016081640A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
US10508151B2 (en) 2014-11-19 2019-12-17 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
KR20170085595A (ko) 2014-12-10 2017-07-24 제넨테크, 인크. 혈뇌 장벽 수용체 항체 및 사용 방법
AU2016353553B2 (en) 2015-11-09 2022-01-20 The University Of British Columbia Amyloid beta epitopes and antibodies thereto
KR102776187B1 (ko) 2015-11-09 2025-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에서의 n-말단 에피토프 및 이에 형태적으로-선택적인 항체
EP3374381A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia EPITOPES IN THE AMYLOID-BETA MEDIUM REGION AND CONFORMITY-SELECTIVE ANTIBODIES THEREOF
CN109476729A (zh) 2016-07-18 2019-03-15 英属哥伦比亚大学 淀粉样蛋白β的抗体
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
JP7434144B2 (ja) 2018-02-27 2024-02-20 株式会社島津製作所 APP669-xのN末端を特異的に認識する抗体、及び免疫測定法
CN113226283A (zh) 2018-10-04 2021-08-06 罗切斯特大学 通过操纵血浆重量摩尔渗透压浓度改善淋巴递送
AR117453A1 (es) 2018-12-20 2021-08-04 Genentech Inc Fc de anticuerpos modificados y métodos para utilizarlas
JP7207517B2 (ja) 2019-03-01 2023-01-18 株式会社島津製作所 App669-711の測定方法、及び測定用キット
CN114026109A (zh) 2019-07-05 2022-02-08 株式会社岛津制作所 β淀粉样蛋白的单克隆抗体、和使用该抗体的β淀粉样蛋白相关肽的测定方法
KR20230039734A (ko) 2020-07-23 2023-03-21 오타이르 프로테나 리미티드 항-Aβ 항체
CN112540180B (zh) * 2020-11-06 2022-03-29 华中科技大学 用于检测人淀粉样蛋白-β双抗夹心ELISA检测试剂盒
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
WO2025250454A1 (en) 2024-05-28 2025-12-04 University Of Rochester Adeno-associated viruses evolved to specifically target human glial progenitor cells in vivo

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ337765A (en) * 1997-04-09 2001-09-28 Mindset Biopharmaceuticals Usa Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease
EP1212422B1 (en) * 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
DE1257584T1 (de) 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
US20020157122A1 (en) * 2000-10-27 2002-10-24 Wong Philip C. Beta-secretase transgenic organisms, anti-beta-secretase antibodies, and methods of use thereof
WO2004029629A1 (en) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
AU2012286021A1 (en) * 2011-07-15 2014-01-16 Janssen Pharmaceutica Nv Monoclonal antibodies specific for beta-amyloid x-37 and uses thereof

Also Published As

Publication number Publication date
AU2003266378B2 (en) 2010-01-21
CN101367875A (zh) 2009-02-18
US9329189B2 (en) 2016-05-03
CA2498058C (en) 2013-02-12
US9939452B2 (en) 2018-04-10
CN101367875B (zh) 2013-06-12
US20060127954A1 (en) 2006-06-15
CY1117387T1 (el) 2017-04-26
HK1081647A1 (zh) 2006-05-19
CN1685236A (zh) 2005-10-19
JP2006513988A (ja) 2006-04-27
EP1546734A1 (en) 2005-06-29
US20170192016A1 (en) 2017-07-06
ES2560853T3 (es) 2016-02-23
AU2003266378A1 (en) 2004-04-19
SI1546734T1 (sl) 2016-02-29
JP6420072B2 (ja) 2018-11-07
JP2014208678A (ja) 2014-11-06
JP2017149719A (ja) 2017-08-31
WO2004029629A1 (en) 2004-04-08
WO2004029630A1 (en) 2004-04-08
PT1546734E (pt) 2016-03-01
CA2498058A1 (en) 2004-04-08
DK1546734T3 (en) 2016-02-08
CN100418984C (zh) 2008-09-17
EP1546734B1 (en) 2015-11-11

Similar Documents

Publication Publication Date Title
DK1546734T3 (en) MONOCLONAL ANTIBODIES AGAINST N-11-TRUNCATED AMYLOID BETA, COMPOSITIONS, PROCEDURES AND APPLICATIONS
EP0683234B2 (en) Antibody against beta-amyloid or their derivative and use thereof
US10208111B2 (en) Alpha-synuclein antibodies and uses thereof
JP3115606B2 (ja) βA4ペプチドに特異的なモノクローナル抗体
US5955317A (en) Antibodies to β-amyloids or their derivatives and use thereof
JP3553592B2 (ja) 可溶性β−アミロイド・ペプチドの検出のための方法及び組成物
EP2189526B1 (en) Antibody binding specifically to tdp-43 aggregate
US5985581A (en) Use of presenilin-1 for diagnosis of alzheimers disease
EP0655626A1 (en) Diagnostic assays for Alzheimer&#39;s disease
JP4374316B2 (ja) β−アミロイドまたはその誘導体に対する抗体およびその用途
JP2955082B2 (ja) ヒトカルシトニンのn末端部分を特異的に認識するモノクローナル抗体
JP4037933B2 (ja) 抗ヒトカルシトニンモノクローナル抗体
JP2014520825A (ja) モノクローナル抗体に対して特異的なβ−アミロイドx−37およびその使用
HK1081647B (en) N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses
HK1126797A (en) N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses
HK1217107B (en) Alpha-synuclein antibodies and uses thereof
JPWO1994017197A1 (ja) β−アミロイドまたはその誘導体に対する抗体およびその用途